Project Grant R41HL184685
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $314K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irvine, CA 92617, USA
Similar Awards
- The National Institutes of Health National Heart Lung and Blood Institute awarded $404,424 to Texas A&M Engineering Experiment Station on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an extracellular matrix–based lymphatic patch with valved pre-collectors that restores lymphatic function and supports unidirectional lymph flow. The project addresses a gap in current regenerative approaches that promote lymphangiogenesis but fail to engineer larger...
- The National Heart, Lung, and Blood Institute awarded Biocircuit Technologies Inc. $379,187 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to optimize and validate Lymph Tape, a microhook-based device for lymphovenous anastomosis (LVA) in the prevention and treatment of lymphedema. Lymph Tape consists of a flexible biologic wrap containing microscale hooks that engage and hold the outer connective tissue of lymphatic vessels and veins, enabling coupling of a...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $950,550 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop translational magnetic resonance imaging technologies that visualize sodium accumulation and lymphatic physiology in lymphedema and lipedema. The research program, titled "Visualizing Sodium in Lymphatic Disease: A Translational Path," pursues three integrated translational goals: understanding disease...
- The National Heart, Lung, and Blood Institute awarded The Administrators of Tulane Educational Fund (Tulane University) $499,736 in Project Grant funding on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports research investigating mechanisms of cholesterol-induced lymphatic dysfunction and whether GLP-1R agonism can improve lymphatic function in obesity and metabolic syndrome. The work addresses lymphedema, a chronic disease affecting more...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $109,696 on June 4, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a postdoctoral research fellow's transition to scientific independence through mentored investigation of apelin receptor signaling in lymphatic vessel function. The project, titled "The Role of Apelin Receptor Signaling in Lymphatic Vessel," will characterize how the apelin...
- The National Heart, Lung, and Blood Institute awarded the University of Southern California $240,206 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 1, 2026, to engineer therapeutically programmed monocytes that adaptively immunomodulate the post-infarction myocardial microenvironment toward cardiac repair and regeneration. The award funds development of smart monocytes using synnotch receptor circuits that detect inflammation and respond by secreting...
- The National Heart, Lung, and Blood Institute awarded Medluidics LLC $227,639 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a cardiopulmonary unit-on-a-chip for investigating right ventricular hypertrophy caused by pulmonary arterial hypertension and for developing targeted treatments. The recipient will develop a microfluidic device that models both the right ventricle and pulmonary artery separated by a collagen layer, enabling culture of...
- The National Heart, Lung, and Blood Institute awarded Cmtx Biotech Inc. $367,988 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a lung-specific, sulfonium lipid nanoparticle formulation of Incyclinide (CMT-3/SLNP) for treating acute respiratory distress syndrome in sepsis patients. This Phase I Small Business Technology Transfer project will evaluate the formulation and delivery of CMT-3/SLNP, a chemically modified, non-antibiotic tetracycline...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Brigham & Womens Hospital Inc. $1,242,222 on March 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate non-coding RNAs as therapeutic targets in chronic limb-threatening ischemia. The funded research addresses the pathophysiology of chronic limb-threatening ischemia (CLTI), a leading cause of amputation in adults affecting over 200 million people globally. The project will...
- The National Heart, Lung, and Blood Institute awarded The University of Iowa $660,875 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on TGF-β signaling in the pathogenesis of lymphangioleiomyomatosis (LAM). The recipient will engineer novel multicellular three-dimensional organoid and lung-on-chip models to test the effects of TGF-β signaling on the growth of LAM nodules and to identify mechanisms that drive nodule growth and alveolar...